Neogenomics vs Bio-Techne
Bio-Techne is the larger business, with $1.22bn of revenue in fiscal 2026 against $727m for Neogenomics (1.7 times as much). Neogenomics grew faster (10.1% against -0.4%). Bio-Techne kept more of each dollar of sales as profit: a net margin of 15.0% against -14.9%.
| Latest fiscal year | NeogenomicsNEO, 2025 | Bio-TechneTECH, 2026 |
|---|---|---|
| Revenue | $727m | $1.22bn |
| Revenue growth | 10.1% | -0.4% |
| Net income | −$108m | $182m |
| Operating margin | — | 20.7% |
| Net margin | -14.9% | 15.0% |
| Return on equity | -12.4% | 9.0% |
| Free cash flow | −$21.8m | $263m |
| Cash | $160m | $265m |
| Total debt | $345m | $200m |
| Debt to equity | — | 9.5% |
| Dividend per share | — | $0.32 |
| Dividend yield | — | 0.4% |
| Share buybacks | — | $41.7m |
| Employees | 2,500 | 3,000 |
| Market value | $2.20bn | $11.35bn |
| Price vs our value range | — | Above our value range |
| Moat score | 34 (Weak) | 76 (Strong) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 2 sales |